What Cosmos Health does

Cosmos Health Inc. (NASDAQ: COSM) is an international diversified healthcare group organized as a holding company of vertically integrated operating subsidiaries. The company was incorporated in Nevada in 2009 and is headquartered in Chicago, Illinois. Cosmos Health operates across three primary business lines: (1) pharmaceutical wholesale distribution through CosmoFarm S.A. (Greece, serving 1,130+ pharmacies in the greater Athens area from 250+ suppliers), Sky Pharm S.A. (Thessaloniki, EU cross-border pharmaceutical trading), and Decahedron Ltd. (UK, MHRA-audited wholesaler); (2) pharmaceutical contract manufacturing and proprietary production through Cana Laboratories S.A. (Athens, EU-GMP-licensed and EMA-certified 54,000 sq ft facility founded 1928) with a cumulative orderbook exceeding 25 million units across nine therapeutic categories; and (3) proprietary nutraceutical and OTC consumer brands including Sky Premium Life (96 SKUs across 27 EU member states via Skroutz), Mediterranation, C-Scrub, C-Sept PRO, the U.S. 18 Series platform (Noor18, Liv18, Cur18, Fort18, Oliv18), and a Korean-developed collagen skincare brand launched in 2026.

Revenue is generated through multiple streams: wholesale drug distribution (transactional, primary revenue driver with CosmoFarm alone running at $60M+ annualized in Q2 2026), contract manufacturing for third-party pharma partners (recurring high-margin managed services), DTC e-commerce sales of proprietary nutraceutical and skincare brands (projected to reach $22.7M+ annualized from the 18 Series at ~75% gross margins within 12-18 months), exclusive licensing for two anticancer drugs valued over $24.5M, planned ZipDoctor telemedicine subscriptions, and a digital asset treasury strategy via a $300M facility. The company also acquired Cloudscreen in January 2024 for AI-based drug repurposing and is deploying operational AI (call center, warehouse, inventory, supply chain) projected to reduce certain operating expenses by up to 30%. FY2025 revenue reached a record $65.3M (+20% YoY) with management guidance projecting $200.6M by FY2029 at a 32% CAGR, contingent on U.S. DTC scale-up, contract manufacturing expansion (including the proposed Doc Pharma acquisition), and execution of the pan-EU distribution strategy. The company employs 51-100 people and operates from Chicago, Athens, Thessaloniki, Harlow (UK), and New York (auditor).

Name

Cosmos Health

Legal name

Cosmos Health Inc.

Website

https://cosmoshealthinc.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

51–100 employees

Short description

Cosmos Health Inc. (NASDAQ: COSM) is a diversified international healthcare group operating vertically integrated pharmaceutical wholesale distribution (CosmoFarm, Sky Pharm, Decahedron), EU-GMP contract manufacturing (Cana Laboratories), and proprietary nutraceutical and OTC consumer brands (Sky Premium Life, 18 Series) across the EU, UK, and U.S.

Ownership category

akta.pro rank

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Wholesale Distribution: Sourcing, procurement, and distribution of branded and generic medicines, OTC pharmaceuticals, food supplements, and medical devices through CosmoFarm (Greece, 1,130+ pharmacy network), Sky Pharm (Greece), and Decahedron (UK) to retail pharmacies and wholesale distributors; primary revenue driver. Q2 2026 CosmoFarm revenue exceeded $15 million representing $60+ million annualized run-rate.
2. Contract Manufacturing Services: Multi-year contract manufacturing agreements through Cana Laboratories for third-party pharmaceutical and wellness partners (Pharmex, Verisfield, Provident, Nassington, Medical Pharmaquality, Libytec); cumulative orderbook exceeding 25 million units across nine therapeutic categories spanning up to 10 years; positioned to generate over $10 million in recurring annual profit at full capacity from EU-GMP and EMA-certified Athens facility.
3. Proprietary Nutraceutical and Skincare DTC Sales: Direct-to-consumer e-commerce sales of proprietary brands Sky Premium Life, Mediterranation, C-Scrub, C-Sept PRO antiseptics, 18 Series nutraceuticals (Noor18, Liv18, Cur18, Fort18, Oliv18), NOOR Collagen, and Korean-developed collagen skincare brand; project $22.7 million+ annualized revenue from 18 Series at ~75% gross margins within 12-18 months.
4. Pharmaceutical Product Licensing: Exclusive licensing rights for two anticancer drugs valued at over $24.5 million; complements contract manufacturing and proprietary product portfolio.
5. Digital Asset Treasury: Crypto and digital asset holdings under $300 million facility, including Bitcoin ($3.1 million) and Ethereum ($2 million) used for balance sheet diversification and shareholder value creation.
6. Planned Telemedicine Subscription (ZipDoctor): Direct-to-consumer subscription-based telemedicine platform acquired via ZipDoctor agreement; planned individual, couple, and family monthly subscription tiers providing unlimited 24/7 access to board-certified physicians and licensed mental health counselors; US English and Spanish coverage via phone or secured video chat.

Pricing tiers

Go-to-market motion5 records

Distribution channels10 records

Marketing channels7 records

Core offering

Cosmos Health is a vertically integrated international healthcare group that manufactures, distributes, and markets proprietary nutraceuticals (Sky Premium Life, Mediterranation, 18 Series including Noor18, Liv18, Cur18, Fort18, Oliv18) and OTC pharmaceutical antiseptics (C-Scrub Wash, C-Sept PRO) under its own brands. It operates an EU-GMP and EMA-certified pharmaceutical manufacturing facility (Cana Laboratories, Athens) producing contract-manufactured products across nine therapeutic categories, and a pharmaceutical wholesale distribution network (CosmoFarm in Greece with 1,130+ pharmacies, Sky Pharm in Greece/Thessaloniki, Decahedron in the UK) sourcing branded and generic medicines, OTC, food supplements, and medical devices to retail pharmacies across 12+ countries.

Product overview

Cosmos Health Inc. (NASDAQ: COSM) is a diversified global healthcare group operating as a holding company with a platform-plus-subsidiaries architecture. Its core operations span nutraceuticals (proprietary brands Sky Premium Life and Mediterranation with sub-products such as ELEONAS, TERRA CRETA, CHIOS MASTIC, OLYMPUS MONS, and PERIVOLI), OTC antiseptics (C-Scrub Wash and C-Sept PRO), the U.S. 18 Series premium nutraceutical platform (Noor18, Liv18, Cur18, Fort18, Oliv18), the newly launched Korean collagen-based skincare brand, and the Cloudscreen AI drug repurposing platform. Pharmaceutical distribution is handled through subsidiaries CosmoFarm S.A. (Greek pharmaceutical wholesaler to over 1,130 pharmacies), Sky Pharm S.A. (EU pharmaceutical trading), and Decahedron Ltd. (UK wholesaler), while contract manufacturing is anchored by Cana Laboratories S.A. (EU-GMP and EMA-certified facility). The ZipDoctor telemedicine platform provides an additional digital health offering.

Differentiator

Problem solved

Functional benefit

Brands

• Sky Premium Life: Proprietary nutraceutical line of nutritional supplements combining carefully selected raw materials, production under strict pharmaceutical standards and GMP protocols.
• Mediterranation
• C-Scrub
• C-Sept PRO
• 18 Series
• Oliv18
• NOOR (NOOR Collagen)

Products and services

• Sky Premium Life Proprietary line of high-quality nutritional supplements combining carefully selected raw materials, production under strict pharmaceutical standards and GMP protocols, and scientifically based selection of nutrients in the right combination and content; 96 SKUs distributed across the UK, Greece, EU, and UAE markets.
• Mediterranation Premium nutritional supplements line inspired by the Mediterranean diet and ancient Greek herbal medicine traditions, complementing the main Sky Premium Life line; produced at the company's Athens facilities under European quality standards.
• C-Scrub Wash (Chlorhexidine 4%) Antimicrobial skin cleanser with chlorhexidine 4% for surgical hand disinfection; passed European testing standard EN 12791:2016+A1:2017, confirming effective antimicrobial activity, available through Tesco, Superdrug, and Amazon in the UK and Greek hospitals.
• C-Sept PRO Antiseptic solution gaining traction across leading Greek public and private hospital groups with annualized sales exceeding $1.3 million at approximately 72% gross margin.
• 18 Series Premium Nutraceutical Platform (Noor18, Liv18, Cur18, Fort18, Oliv18) Premium clinical-evidence nutraceutical platform for the U.S. market requiring all products to meet three criteria: patented ingredient, peer-reviewed clinical evidence, and exact dose used in published studies; long-term target of 18 clinically validated products including Noor18 (marine collagen), Liv18 (liver fat), Cur18 (curcumin), Fort18 (men's stamina), and Oliv18 (olive polyphenol).
• Korean Collagen-Based Skincare Brand Premium Korean-developed collagen-based skincare brand launched into the global beauty and personal care market via direct-to-consumer model in the United States; multi-brand portfolio strategy targeting higher-margin consumer categories.
• Cloudscreen AI Drug Repurposing Platform AI platform specialized in drug repurposing, acquired by Cosmos Health to enter the global drug repurposing market valued at over $25 billion; leverages artificial intelligence to identify new therapeutic indications for existing compounds.
• ZipDoctor Telemedicine Platform Direct-to-consumer subscription-based telemedicine platform providing affordable unlimited 24/7 access to board-certified physicians and licensed mental and behavioural health counsellors and therapists across the United States; offers English and Spanish coverage via phone or secured video chat.
• Cana Laboratories Contract Manufacturing Services Greek pharmaceutical contract manufacturer founded in 1928 with a 54,000-square-foot EU-GMP-licensed and EMA-certified Athens facility; received approximately $5.5 million in upgrades including a new ACG capsule-filling line; positioned to generate over $10 million in recurring annual profit at full capacity. Manufactures and distributes proprietary pharmaceutical and health-related products and contract manufactures for partners including AstraZeneca, Janssen, Merck, Viatris, Nestle, Unilever, and P&G.
• CosmoFarm Pharmaceutical Distribution Fully licensed pharmaceutical wholesale company founded in 1994 operating in the greater Athens area; approved by the National Organization for Medicines under Good Distribution Practices to distribute branded and generic medicines, OTC pharmaceuticals, food supplements, and medical devices to a network of more than 1,130 pharmacies.

Quantifiable outcome

• C-Sept PRO achieving $1.3M+ annualized sales at ~72% gross margin in Greek hospitals
• +8 more outcomes

Named customers17 records

Segments7 records

Ideal customer profiles7 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability11 records

Feature5 records

Partnerships

15 partnerships are on record, tiered core, flagship and minor.

• Pharmex S.A.coreChannel Partner/ Reseller/ Distributor · 17 June 2026Five-year contract manufacturing agreement with Cana Laboratories to produce approximately 2.86 million units of three dermatological pharmaceutical products: BETAFUSIN (Betamethasone/Fusidic Acid Cream, 2.25M units), BOTAFEX (Minoxidil Cutaneous Solution, 325,000 units), and BUDESODERM (Budesonide Cream/Cutaneous Solution, 285,000 units) at Cana's EU-GMP-licensed, EMA-certified facility. Supports higher utilization of EU manufacturing capacity and recurring revenue from higher-margin contract manufacturing activities.
• Doc PharmaflagshipStrategic or Co-development Partner · 14 June 2026Non-binding letter of intent to acquire 100% of Doc Pharma, a European pharmaceutical manufacturer with GMP certifications. Doc Pharma brings asset base of approximately $24 million, average annual revenue of about $6.7 million, average annual gross profit of approximately $3.2 million, and a GMP-licensed manufacturing facility spanning approximately 59,000 square feet. Expected to be immediately accretive and strengthen vertical integration strategy; requires independent committee review, fairness opinion, and shareholder approval due to Doc Pharma being a related-party entity.
• NassingtonminorChannel Partner/ Reseller/ Distributor · 12 June 2026New contract manufacturing order with Cana Laboratories for 253,657 units across a range of pharmaceutical products including oral solutions, tablets, sprays, and rectal creams. Reflects demand for Cana's contract manufacturing capabilities and strength of the vertically integrated platform under European GMP certification.
• Verisfield S.A.coreChannel Partner/ Reseller/ Distributor · 10 June 2026Three-year contract manufacturing agreement with Cana Laboratories to produce 3.9 million units of VASCLOR GEST (progesterone) 400mg vaginal pessaries (1.3 million units annually) indicated for luteal phase support and assisted reproduction treatment. Additionally, 253,657 units contract manufacturing orders across oral solutions, tablets, sprays, and rectal creams. Marks Cana's expansion into women's health and reproductive medicine; Verisfield markets over 60 pharmaceutical products across seven therapeutic categories in Greece and internationally.
• Provident PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 9 June 2026Five-year contract manufacturing agreement with Cana Laboratories to produce 385,000 units of CERTORUN (sertraline hydrochloride) antidepressant in 50mg and 100mg capsule strengths at an annual volume of 77,000 units. Production uses Cana's newly installed ACG capsule-filling line as part of ongoing European GMP-certified manufacturing upgrades. CEO Greg Siokas stated this is a core pillar of the long-term growth strategy, generating high-margin recurring revenue with cash flow visibility.
• Cloudpharm P.C.coreStrategic or Co-development Partner · 8 June 2026Acquired international patent application WO2025108566A1 covering nanotechnology-based pharmaceutical, nutraceutical, OTC, and specialized healthcare product development. Plans to integrate the patented technology with Cana Laboratories' European GMP-certified manufacturing platform and pursue national and regional patent protection in key international markets. Strengthens transition from AI-enabled discovery to proprietary product development and commercialization.
• SkroutzflagshipChannel Partner/ Reseller/ Distributor · 4 June 2026Leading Southeast European e-commerce platform providing pan-European distribution for Sky Premium Life brand across all 27 EU member states. 96 Sky Premium Life nutraceutical and wellness products now accessible to consumers throughout Western, Northern, and Central and Eastern Europe via Skroutz's cross-border infrastructure. Represents key milestone in international growth strategy.
• PharmalinkflagshipChannel Partner/ Reseller/ Distributor · 13 April 2026Exclusive distributor of Sky Premium Life products in the UAE. Third consecutive 60,000-unit purchase order bringing cumulative orders to 270,000 units since partnership began June 2024. Pharmalink operates with ~1,400 employees, 120+ partners, and 3,000+ pharmacies including MEDICINA chain (~200 locations). Goal of 3 million cumulative units over five years of partnership; partnership commenced June 2024.
• TescoflagshipChannel Partner/ Reseller/ Distributor · 18 February 2026C-Scrub Wash Chlorhexidine 4% antimicrobial skin cleanser now available through Tesco, the UK's largest retailer with nearly 30% market share. Listed on Tesco's online platform; establishes a platform for potentially rolling out additional Cosmos Health products in the UK and broader European markets.
• SuperdrugflagshipChannel Partner/ Reseller/ Distributor · 18 February 2026C-Scrub Wash Chlorhexidine 4% available through Superdrug, the UK's second-largest beauty and health retailer. Superdrug operates 830+ stores across the UK and Republic of Ireland, including 200+ in-store pharmacies and a growing number of health clinics, complemented by an e-commerce platform. Reinforces growing retail momentum for C-Scrub.
• DolCas BiotechflagshipOEM/ Whitelabel/ Licensing Partner · 24 December 2025Manufacturing agreement for U.S. domestic manufacturing capacity to mitigate tariff impacts and strengthen supply chain resilience. Supports Cosmos Health's U.S. nutraceutical expansion including the 18 Series platform; aims to extend vertically integrated platform across pharmaceuticals, nutraceuticals, and OTC products into North America.
• Prime Ledger LLCflagshipStrategic or Co-development Partner · 3 December 2025Long-term strategic partnership to digitally transform Cosmos Health's financial operations. Multi-phase agreement commencing Q4 2025 will establish a compliant framework for Digital Asset Treasury management and integrate Cosmos Health's data infrastructure using Prime Ledger's existing relationship with Conduit Network. Includes management of a $300 million treasury facility and tokenization of high-value intellectual property assets. Initial phase focuses on strategy, regulatory compliance, and platform design.
• Medical Pharmaquality S.A.coreChannel Partner/ Reseller/ Distributor · 25 September 2025Contract manufacturing agreement with Cana Laboratories to produce 3 million MYCOFAGYL pessaries per year (dual-action vaginal infection treatment combining Metronidazole and Nystatin). Expands Cana's manufacturing portfolio into gynecology with high-margin recurring revenue and reinforces position as a trusted pharmaceutical manufacturing partner across Europe.
• Cloudscreen (AI Platform)flagshipTechnology or Integration · 23 January 2024Completed acquisition of Cloudscreen, an AI platform specialized in drug repurposing, entering the global drug repurposing market valued at over $25 billion. The acquisition was noted as a notable strategic move in the AI in drug repurposing market report covering the sector projected to grow from $0.87 billion in 2024 to $2.19 billion by 2029. The platform supports Cosmos Health's broader AI strategy for R&D and proprietary drug development.
• Libytec Pharmaceutical S.A.minorChannel Partner/ Reseller/ DistributorManufacturing agreement with Cana Laboratories for the pharmaceutical product PathMuscle. Supports diversification of contract manufacturing customer base and product portfolio.

Scale indicators17 records

Recent moves8 records

Expansion highlights8 records

Direct peers

• USANA Health Sciences: USANA develops and sells premium nutritional supplements and personal care products, comparable to Cosmos Health's Sky Premium Life and Mediterranation nutraceutical lines. Both companies target premium consumer health segments with branded products, although USANA uses a direct-selling/network marketing model while Cosmos Health uses DTC and retail channels.
• Nu Skin Enterprises: Nu Skin is a direct-selling personal care and nutritional supplement company with premium branded products. Comparable to Cosmos Health's 18 Series and Korean collagen skincare brand for premium DTC consumer health positioning, though Nu Skin operates at much larger scale with a global direct-selling model.
• Herbalife Nutrition: Herbalife is a global nutrition company selling meal replacement shakes, supplements, and personal care products through a direct-selling model. Comparable to Cosmos Health's branded nutraceutical portfolio targeting premium consumer health and wellness categories, though Herbalife operates at substantially larger global scale.

Regional players

• DEMO S.A. DEMO is one of Greece's largest pharmaceutical manufacturers with broad generic pharmaceutical and consumer health portfolios. Comparable to Cosmos Health's Cana Laboratories contract manufacturing and proprietary pharmaceutical operations within the Greek market. Advisory board member Dimitris Moraitis has previously held senior roles at DEMO.
• VIANEX S.A. VIANEX is a major Greek pharmaceutical company with manufacturing and distribution of branded generics and OTC products. Comparable to Cosmos Health's vertically integrated Greek pharmaceutical operations including Cana Laboratories manufacturing and CosmoFarm/Sky Pharm distribution. Advisory board member Dimitris Moraitis has held senior positions at VIANEX.
• Elpen Pharmaceutical: Elpen is a Greek pharmaceutical manufacturer with branded generics and OTC products across multiple therapeutic categories. Comparable to Cosmos Health's Cana Laboratories manufacturing platform serving Greek and European pharmaceutical markets with contract manufacturing and proprietary brands.

Broad incumbents

• Recipharm (Toulouse): Recipharm is a major European pharmaceutical contract development and manufacturing organization (CDMO) offering formulation, manufacturing, and supply across multiple therapeutic categories. Comparable to Cosmos Health's Cana Laboratories EU-GMP/EMA-certified contract manufacturing platform, though Recipharm operates at substantially larger scale across many geographies.
• Teladoc Health: Teladoc is a leading U.S. telemedicine platform offering 24/7 virtual physician and mental health services via subscription and per-visit models. Comparable to Cosmos Health's planned ZipDoctor U.S. telemedicine subscription offering individual, couple, and family tiers with 24/7 access to board-certified physicians.
• McKesson Corporation: McKesson is a global pharmaceutical distribution and healthcare services giant. Comparable to Cosmos Health's pharmaceutical wholesale operations (CosmoFarm, Sky Pharm, Decahedron) as both operate pharmaceutical distribution to retail pharmacies and wholesale customers, though McKesson operates at vastly larger global scale.

Emerging players

• Hims & Hers Health: Hims & Hers is a U.S. consumer health platform offering telehealth consultations and DTC prescription and OTC products including supplements and personal care. Comparable to Cosmos Health's ZipDoctor telemedicine platform and 18 Series DTC nutraceutical launches targeting U.S. consumers through digital channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CosmosHealthInc
• Facebookfacebook.com/CosmosHealthInc
• LinkedInlinkedin.com/company/cosmos-health-inc

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries6 records

Funding overview

Funding rounds6 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cosmos Health